European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

The majority of patients with chronic myeloid leukemia in chronic phase gain substantial benefit from imatinib but some fail to respond or lose their initial response. In 2006, the European LeukemiaNet published recommendations designed to help identify patients responding poorly to imatinib. Patien...

Full description

Saved in:
Bibliographic Details
Published in:Blood
Main Authors: Marin, David, Milojkovic, Dragana, Olavarria, Eduardo, Khorashad, Jamshid S., de Lavallade, Hugues, Reid, Alistair G., Foroni, Letizia, Rezvani, Katayoun, Bua, Marco, Dazzi, Francesco, Pavlu, Jiri, Klammer, Matthias, Kaeda, Jaspal S., Goldman, John M., Apperley, Jane F.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2008
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143157/
https://ncbi.nlm.nih.gov/pubmed/18716134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-06-162388
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items